There seems to be something stirring deep in the bowels of MYX. The E4 announcement by Mithra may have been the catalyst as it was certainly informative and helped give a greater understanding of the environmental benefits of E4.
So my question is: is the potential of E4, a 2021 story and the pending Nuvaring FDA approval enough to start to move the Mayne Pharma share price upwards significantly?
Thoughts?
MYX Price at posting:
48.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)